Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable (dose-escalation stage only)
Documented locally advanced or metastatic NSCLC in patients who have failed at least one prior chemotherapy-based regimen for incurable disease (cohort-expansion stage only)
Adequate organ function as assessed by laboratory tests
Evaluable disease or disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST)
Agreement to use an effective form of contraception for the duration of the study
You may not be if
Any anti-cancer therapy (e.g., chemotherapy, biologic therapy, or hormonal therapy) within a specified timeframe prior to first study treatment
Prior treatment with PI3K pathway-inhibiting agents (cohort-expansion stage only)
History of Grade \>= 3 fasting hyperglycemia or diabetes requiring regular medication
Current clinically significant and uncontrolled systemic disease (e.g., cardiovascular, pulmonary, or metabolic)
History of clinically significant cardiac or pulmonary dysfunction
History of malabsorption syndrome or other condition that would interfere with enteral absorption
Clinically significant history of liver disease
Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytic agents
Active autoimmune disease and/or need for corticosteroid therapy
Known brain metastases that are untreated, symptomatic, or require therapy
